{"id":13218,"date":"2010-07-16T11:00:00","date_gmt":"2010-07-16T09:00:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/novartis-11-fatturato-secondo-trimestre-utile-netto-a-19\/"},"modified":"2010-07-16T11:00:00","modified_gmt":"2010-07-16T09:00:00","slug":"novartis-11-fatturato-secondo-trimestre-utile-netto-a-19","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novartis-11-fatturato-secondo-trimestre-utile-netto-a-19\/","title":{"rendered":"Novartis, +11% second quarter revenue, net income at +19%"},"content":{"rendered":"

 <\/p>\n

\"Joseph Joseph Jimenez of Novartis<\/em><\/p>\n

Solid financial performance in the second quarter of 2010 for the Swiss pharmaceutical company Novartis: revenues grow by 11% (+12% in constant currency, vc) to 11.7 billion dollars. Earnings per share (Eps) recorded an increase of 18% (+17% in cc), to 1.06 dollars, while, net of exceptional events, it grew by 14% (+14% in cc), to 1.20 dollars. <\/p>\n

<\/font><\/font><\/p>\n

Group volumes grew by up to 12 percentage points, prices detracted by one point and acquisitions contributed by one point. Pharmaceuticals ($7.7B, +8%) made progress across all regions and confirmed solid growth in volumes. Vaccines & Diagnostics ($0.6 billion, +135%) posted a substantial increase, including $0.2 billion from rights to sell the pandemic A(H1N1) vaccine. Sandoz ($2 billion, +13%) grows on successful new product launches and contribution from Ebewe Pharma. All Consumer Health businesses ($1.5 billion, +7%) delivered solid performances. <\/p>\n

<\/font><\/font><\/p>\n

As for half-yearly revenues, the figure is up by 18% (+15% in vc), to 23.8 billion dollars, while EPS grows in the first six months of the year by 33% (+28%) to 2.34 dollars . Eps net of exceptional events increased by 29% (+24% in cv), to 2.65 dollars.<\/p>\n

<\/font><\/font><\/p>\n

Commenting on the results, Novartis Chief Executive Officer Joseph Jimenez said, "I am pleased that, in the second quarter of 2010, Novartis once again delivered solid double-digit growth, outpacing the market. These results were driven by our successes in innovation, with recently launched products contributing 21% to Group revenue. <\/p>\n

<\/font><\/font><\/p>\n

We are making significant progress on each of our three strategic priorities: innovation, growth and productivity."<\/p>\n

<\/font><\/font><\/p>\n

(BDC) Pharmakronos \u2013 July 16, 2010  \"\"<\/a><\/em><\/font><\/font><\/p>\n

Novartis net income up +19% in Q2 2010<\/p>\n

<\/strong><\/font><\/p>\n

In Q2 2010 Novartis reported a 19% increase in<\/p>","protected":false},"excerpt":{"rendered":"

   Joseph Jimenez of Novartis Solida performance finanziaria nel secondo trimestre 2010 per l’azienda farmaceutica svizzera Novartis: il fatturato cresce dell’11% (+12% in valuta costante, v.c.) a 11,7 miliardi di dollari. L’utile per azione (Eps) registra un incremento del 18% (+17% v.c.), a 1,06 dollari, mentre, al netto degli eventi eccezionali, cresce del 14% (+14% …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13218","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13218"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13218\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}